J&J Voluntarily Recalls Rolaids Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Voluntarily Recalls Rolaids Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

McNeil Consumer Healthcare, a division of McNEIL-PPC, part of Johnson & Johnson (J&J, New Brunswick, NJ) issued a voluntary recall on Dec. 9, 2010, for Rolaid products in the United States and Canada due to reports of possible product contamination. The recall is the latest of several product recalls by J&J’s consumer healthcare business relating to problems in quality control and quality assurance in its manufacturing activities.   

McNeill is voluntarily recalling of lots of Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews, and Rolaids Multi-Symptom plus Anti-Gas Softchews distributed in the United States. McNeil also is voluntarily recalling all lots of Rolaids Ultra Strength SoftChews and Rolaids Ultra Strength SoftChews plus Gas Relief distributed in Canada.

McNeil said it is taking this action following some consumer reports of foreign materials in the product, including metal and wood particles. McNeill said that a company investigation has determined that the materials were potentially introduced into the product during the manufacturing process at a third-party manufacturer. The company also has suspended production of these products and said it will not restart production until corrective actions have been implemented.

See related stories:
A Timeline of J&J/McNeil’s Recent Recall Troubles (PharmTech blog)

FDA Testifies to Congress Regarding J&J Recalls, Quality Concerns  (ePT)

J&J Voluntarily Recalls Certain OTC products (ePT)

J&J Voluntarily Recalls Certain OTC Products Because of Manufacturing Problems (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here